Crinetics Pharmaceuticals, Inc. (CRNX) |
|
20.4 0.43 (2.15%)
|
01-27 16:00 |
|
Open: |
19.97 |
Pre. Close: |
19.97 |
|
High:
|
20.96 |
Low:
|
19.88 |
|
Volume:
|
649,362 |
Market Cap:
|
1,098(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:43:34 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 25.28 One year: 29.53 |
| Support: |
Support1: 17.88  Support2: 15.55 |
| Resistance: |
Resistance1: 21.64 Resistance2: 25.28 |
| Pivot: |
18.71 |
| Moving Average: |
MA(5): 20.25 MA(20): 18.51
MA(100): 18.25 MA(250): 19.23 |
| MACD: |
MACD(12,26): 0.8 Signal(9): 0.5 |
| Stochastic oscillator: |
%K(14,3): 79.9  %D(3): 83.4 |
| RSI: |
RSI(14): 63.8 |
| 52-week: |
High: 27.86 Low: 15.36 |
| Average Vol(K): |
3-Month: 358 (K) 10-Days: 464 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CRNX ] has closed below upper band by 20.8%. Bollinger Bands are 88.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
20.98 - 21.07 |
21.07 - 21.14 |
|
Low:
|
19.66 - 19.76 |
19.76 - 19.84 |
|
Close:
|
20.23 - 20.39 |
20.39 - 20.53 |
|
Company Description |
|
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. |
Headline News |
Sat, 28 Jan 2023
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) Has Made The ... - Marketing Sentinel
Thu, 26 Jan 2023
As the world becomes increasingly uncertain, Crinetics ... - The Dwinnex
Wed, 25 Jan 2023
Is it Time to Dump Crinetics Pharmaceuticals Inc (CRNX) Stock After it Has Gained 11.66% in a Week? - InvestorsObserver
Fri, 20 Jan 2023
Is Crinetics Pharmaceuticals Inc (CRNX) a Bad Choice in Biotechnology Friday? - InvestorsObserver
Mon, 09 Jan 2023
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Mon, 28 Nov 2022
Crinetics Pharmaceuticals Provides Update on CRN04777 Program - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
54 (M) |
|
% Held by Insiders
|
4.019e+007 (%) |
|
% Held by Institutions
|
2.7 (%) |
|
Shares Short
|
3,860 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.5028e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
961.5 |
|
Return on Equity (ttm)
|
-31.9 |
|
Qtrly Rev. Growth
|
5.11e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-56.65 |
|
EBITDA (p.s.)
|
-8.57526e+007 |
|
Qtrly Earnings Growth
|
-2.9 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-103 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.37 |
|
Price to Cash Flow
|
3.03 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
3.61e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
